Scynexis (SCYX) Total Non-Current Liabilities (2013 - 2026)
Scynexis (SCYX) reported Total Non-Current Liabilities of $17.5 million for Q1 2026, up 41.78% on a YoY basis from $12.3 million in Q1 2025, and up 135.08% quarter-over-quarter from $7.4 million in Q4 2025.
Scynexis (SCYX) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Scynexis has reported Total Non-Current Liabilities for 14 years, with the latest figure at $17.5 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 41.78% year-over-year to $17.5 million; the trailing twelve-month figure through Mar 2026 stood at $17.5 million (up 41.78% YoY), and the FY2025 full-year result was $7.4 million, down 73.06% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $17.5 million, up from $7.4 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $90.2 million in Q3 2022, with the low at $7.4 million in Q4 2025.
- Historically, Total Non-Current Liabilities has averaged $36.9 million across 5 years, with a median of $31.7 million in 2023.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 59.74% — and 2025, when it plunged 73.06%.
- Scynexis' Total Non-Current Liabilities stood at $65.9 million in 2022, then sank by 48.78% to $33.8 million in 2023, then declined by 18.37% to $27.6 million in 2024, then tumbled by 73.06% to $7.4 million in 2025, then soared by 135.08% to $17.5 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $17.5 million (Q1 2026), $7.4 million (Q4 2025), and $11.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | Scynexis | 225.23 Mn | 165.97 Mn | - | 17.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.46 Mn |
| Dec 31, 2025 | 7.43 Mn |
| Sep 30, 2025 | 11.10 Mn |
| Jun 30, 2025 | 13.32 Mn |
| Mar 31, 2025 | 12.31 Mn |
| Dec 31, 2024 | 27.57 Mn |
| Sep 30, 2024 | 29.30 Mn |
| Jun 30, 2024 | 29.44 Mn |
| Mar 31, 2024 | 31.95 Mn |
| Dec 31, 2023 | 33.77 Mn |
| Sep 30, 2023 | 32.92 Mn |
| Jun 30, 2023 | 31.69 Mn |
| Mar 31, 2023 | 59.89 Mn |
| Dec 31, 2022 | 65.93 Mn |
| Sep 30, 2022 | 90.19 Mn |
| Jun 30, 2022 | 68.90 Mn |
| Mar 31, 2022 | 64.71 Mn |
| Dec 31, 2021 | 75.23 Mn |
| Sep 30, 2021 | 70.17 Mn |
| Jun 30, 2021 | 64.36 Mn |